Christopher J. Tien, PhD awarded pilot grant
Christopher J. Tien, PhD, assistant professor and lead physicist for Brachytherapy in the Department of Therapeutic Radiology in the Yale School of Medicine, was recently awarded a pilot grant from the American Cancer Society and Yale Cancer Center for his application “Characterization of a novel brachytherapy applicator with dynamic shielding for radiation therapy in cervical cancer.” As Dr. Tien is a clinical physicist, this grant represents his first extramural funding. Other members of the Yale Cancer Center will be key collaborators on the work, specifically: Dr. Emily Draeger, Dr. Jay (Zhe) Chen, and Dr. Shari Damast.
Jeremy Kortmansky, MD, in Recognition of Colorectal Cancer Awareness Month
Jeremy Kortmansky, MD, Associate Professor of Clinical Medicine (Medical Oncology); Associate Chief Medical Officer, Network Medical Services; Chief Medical Officer, Smilow Cancer Hospital; Clinical Director, Division of GI Medical Oncology, Yale Cancer Center, comments on Colorectal Cancer Awareness Month.
2 AstraZeneca lung cancer drugs perform well in late-stage trials
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy before surgery and use after surgery demonstrated a statistically significant improvement in event-free survival versus chemotherapy alone, followed by surgery for patients with resectable early-stage non-small cell lung cancer.Source: Delaware Business Now
Tagrisso demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
Positive high-level results from the ADAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent.Source: AstraZeneca
FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC
Dr Herbst discusses the FDA approval of adjuvant pembrolizumab in non–small cell lung cancer, key efficacy and safety data from the KEYNOTE-091 trial, and future research efforts that may further improve outcomes in this population.Source: OncLive
Involving Hospitalists in Inpatient Cancer Care Reduces Patient Stays, Oncologist Stress
Involving hospitalists in the co-management of care for patients with cancer is associated with decreased length of hospital stay for patients, increased inpatient hospital capacity, and reduced stress among oncologists – all while maintaining high-quality inpatient care, according to a new study from Yale Cancer Center and Smilow Cancer Hospital. The study was published March 9 in the Journal of Hospital Medicine.
Bosenberg named Brady Professor of Dermatology, Pathology and Immunobiology
Dr. Marcus Bosenberg, an accomplished clinician, teacher, and researcher who studies the factors that regulate anti-cancer immune responses, was recently appointed the Anthony N. Brady Professor of Dermatology, Pathology, and Immunobiology, effective immediately.Source: Yale News